Pfizer Inc. (NYSE:PFE) Holdings Decreased by Cypress Wealth Services LLC

Cypress Wealth Services LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.6% during the first quarter, Holdings Channel.com reports. The firm owned 19,076 shares of the biopharmaceutical company’s stock after selling 3,517 shares during the period. Cypress Wealth Services LLC’s holdings in Pfizer were worth $529,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Baugh & Associates LLC raised its stake in shares of Pfizer by 34.4% during the first quarter. Baugh & Associates LLC now owns 171,506 shares of the biopharmaceutical company’s stock valued at $4,759,000 after purchasing an additional 43,907 shares in the last quarter. Congress Park Capital LLC raised its stake in shares of Pfizer by 10.2% during the first quarter. Congress Park Capital LLC now owns 21,640 shares of the biopharmaceutical company’s stock valued at $601,000 after purchasing an additional 2,000 shares in the last quarter. Tarbox Family Office Inc. raised its stake in shares of Pfizer by 2.4% during the first quarter. Tarbox Family Office Inc. now owns 29,724 shares of the biopharmaceutical company’s stock valued at $825,000 after purchasing an additional 684 shares in the last quarter. 180 Wealth Advisors LLC raised its stake in shares of Pfizer by 3.1% during the first quarter. 180 Wealth Advisors LLC now owns 28,489 shares of the biopharmaceutical company’s stock valued at $791,000 after purchasing an additional 857 shares in the last quarter. Finally, Stokes Capital Advisors LLC bought a new stake in shares of Pfizer during the first quarter valued at about $203,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Up 1.4 %

PFE traded up $0.38 during trading on Thursday, reaching $27.80. The company had a trading volume of 27,944,899 shares, compared to its average volume of 40,970,031. The firm’s 50-day simple moving average is $27.81 and its 200 day simple moving average is $27.69. The company has a market cap of $157.53 billion, a price-to-earnings ratio of -458.26, a PEG ratio of 1.10 and a beta of 0.70. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.80. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05.

Pfizer (NYSE:PFE) last released its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter in the previous year, the business posted $1.23 EPS. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. Equities research analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 6.04%. Pfizer’s dividend payout ratio (DPR) is presently -2,799.53%.

Analyst Ratings Changes

Several brokerages have commented on PFE. Morgan Stanley boosted their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat, Pfizer has an average rating of “Hold” and a consensus target price of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.